South Africa Anticoagulant Market is expected to grow with the CAGR of 5.1% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:
Access full Report @https://www.databridgemarketresearch.com/de/reports/south-africa-anticoagulant-market
South Africa anticoagulant market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in South Africa anticoagulant market are introducing strong range of products portfolio along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.
For instance
- In March 2020, Bayer AG received positive efficacy data related to use of Xarelto in adults suffering from excessive bleeding after orthopaedic surgery of lower limb. This positive clinical trial result paved the way for company to get product approval for treatment of vast conditions.
Cipla Inc. is the dominating player in South Africa anticoagulant market. The other key players existing in the market includes Sanofi, Fresenius Kabi AG (A subsidiary of Fresenius SE & Co KGaA), Aspen Holdings, Bayer AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Adcock Ingram among others.
Cipla Inc.
Cipla Inc. headquartered is in Mumbai, India, mainly focuses on manufacturing of high quality and affordable medicines in order to support patients in need. The company has two business segments including Pharmaceuticals, New Ventures. In these Pharmaceuticals is the market focussed segment. The company has wide product portfolio such as over the counter, featured product, scheduled in which scheduled is the market focused category.
- In February 2019, Cipla signed an agreement with Wellthy Therapeutics Private Limited in order to provide digital therapeutics to patients suffering from cardiovascular disease. As the company is engaged in providing anticoagulants for treatment and prevention of cardiovascular disease, this partnership helped the company to enhance its anticoagulant platform by accessing all related information through launched digital platform.
The company has wide presence across U.S., Australia, Europe, SAGA (South Africa, Sub- Saharan Africa, Global Access. The company also has various subsidiary companies such as Cipla BioTec Pvt. Ltd. (India), Cipla Health Ltd. (India), Cipla Australia Pty. Ltd. (Australia), Cipla USA Inc. (U.S), Cipla Medpro Holdings Proprietary Ltd. (South Africa), Cape to Cairo Exports ProprietaryLtd.(South Africa) among others.
Bayer AG
Bayer AG headquartered in Leverkusen, Germany was founded in 1863. The company focuses on towards creating value for their customers, stockholders and employees while strengthening the company's earning power. The company has wide product portfolio including pharmaceuticals, consumer health, crop science, animal health in which pharmaceuticals is the market focused category.
- In April 2019, Bayer AG received positive clinical data related to Xarelto for prevention and treatment of stroke in patients having atrial fibrillation. This positive clinical trial result helped the company to get early product approval.
The company has wide presence across Africa, Asia, Australia, & New Zealand, Europe, Latin America and Middle East and North America. The company also has various subsidiary companies such as Bayer Algerie S.P.A. (Algeria), Bayer S.A. (Argentina), Monsanto Argentina SRL (Argentina), Bayer CropScience Holdings Pty Ltd (Australia), Bayer NV (Belgium), Bayer S.A (Brazil) and many more.
Pfizer Inc.
Pfizer Inc. headquartered in New York, U.S. was founded in 1849. The company focuses on providing standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. The company is engaged in providing wide range of product categories such as Elelyso, Accupril, Aldactone, Caduet, Carbocaine, Eliquis, Emcyt, Fragmin among others in which Eliquis and Fragmin is the market focused product category.
- In December 2019, Bristol-Myers Squibb-Pfizer Alliance received world data regarding safety and efficacy of Eliquis for the treatment of venous thromboembolism in patients suffering from active stage cancer. This positive data helped the company to offer patients and physicians with growing opportunity to treat venous thromboembolism that lead to more product sales.
The company is present in North America, South America, Middle East & Africa, Asia-Pacific, Europe. The company has several owned subsidiaries involving Pfizer Animal Health B.V. (The Netherlands), Pfizer Asia International B.V. (The Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A.(Dominican Republic), Pfizer Egypt S.A.E.(Egypt) among others.
